ATE507242T1 - Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon - Google Patents

Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon

Info

Publication number
ATE507242T1
ATE507242T1 AT06755161T AT06755161T ATE507242T1 AT E507242 T1 ATE507242 T1 AT E507242T1 AT 06755161 T AT06755161 T AT 06755161T AT 06755161 T AT06755161 T AT 06755161T AT E507242 T1 ATE507242 T1 AT E507242T1
Authority
AT
Austria
Prior art keywords
binding molecules
host cell
applications
specific binding
human binding
Prior art date
Application number
AT06755161T
Other languages
English (en)
Inventor
Mark Throsby
Kruif Cornelis De
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE507242T1 publication Critical patent/ATE507242T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06755161T 2005-05-12 2006-05-11 Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon ATE507242T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP05/52160 2005-05-12
EPPCT/EP05/52648 2005-06-08
EPPCT/EP05/52946 2005-06-23
EPPCT/EP05/54002 2005-08-15
PCT/EP2006/062250 WO2006120230A2 (en) 2005-05-12 2006-05-11 Host cell specific binding molecules capable of neutralizing viruses and uses thereof

Publications (1)

Publication Number Publication Date
ATE507242T1 true ATE507242T1 (de) 2011-05-15

Family

ID=37396920

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06755161T ATE507242T1 (de) 2005-05-12 2006-05-11 Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon

Country Status (7)

Country Link
US (2) US8052974B2 (de)
EP (1) EP1879921B1 (de)
AT (1) ATE507242T1 (de)
AU (1) AU2006245734C1 (de)
CA (1) CA2608058C (de)
IL (1) IL187321A (de)
WO (1) WO2006120230A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
EP2395016A3 (de) 2003-05-30 2012-12-19 Merus B.V. Entwurf und Verwendung von gepaarten unterschiedlichen Regionen von spezifisch bindenden Molekülen
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
NZ580607A (en) 2004-05-27 2011-05-27 Crucell Holland Bv Binding molecules capable of neutralizing rabies virus and uses thereof
US8052974B2 (en) 2005-05-12 2011-11-08 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
JP2013538042A (ja) 2010-06-16 2013-10-10 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション エンドプラスミンに対する抗体およびその使用
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
KR101815265B1 (ko) * 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
CA3212977A1 (en) 2014-02-11 2015-08-20 Visterra, Inc. Antibody molecules to dengue virus and uses thereof
EP3262411B1 (de) * 2015-02-25 2022-04-06 Vanderbilt University Antikörper-vermittelte neutralisierung von marburg-virus
WO2016168758A1 (en) * 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
EP3297673A4 (de) * 2015-05-22 2019-05-08 Memorial Sloan-Kettering Cancer Center Für ein prame-peptid spezifische t-zell-rezeptor-ähnliche antikörper
CN109311986A (zh) 2016-03-25 2019-02-05 威特拉公司 登革热病毒抗体分子的制剂
JP7324744B2 (ja) 2017-08-21 2023-08-10 アダジーン インコーポレイテッド ダイナミックヒト抗体軽鎖ライブラリー
CA3072143A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Dynamic human heavy chain antibody libraries

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529700A (en) 1982-08-20 1985-07-16 University Of Miami Hybridoma cells secreting a monoclonal antibody specific for 5-bromo and 5-iodoeoxyuridine and reagents for measuring cellular proliferation
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
DE69233770D1 (de) 1991-09-19 2009-10-29 Us Health Chimäre und/oder wachstumgehemmte Flaviviren
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
HU224199B1 (hu) 1994-07-08 2005-06-28 Baxter Aktiengesellschaft Flavivírus-fertőzések elleni immunizálásra alkalmas, csupasz nukleinsavat tartalmazó vakcina
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6455509B1 (en) 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
WO1998006822A1 (fr) 1996-08-08 1998-02-19 Yoshitomi Pharmaceutical Industries, Ltd. Milieu de culture et ses applications
DK0934526T3 (da) 1996-10-08 2003-05-05 Bisys B V U Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
ES2345614T3 (es) 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
WO1999026653A1 (en) 1997-11-20 1999-06-03 United States Army Medical Research And Material Command Dna vaccines against tick-borne flaviviruses
CA2331368C (en) 1998-06-04 2009-02-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acid vaccines for prevention of flavivirus infection
TR200100642T2 (tr) 1998-08-25 2001-07-23 Yale University Helioksantin ve analogları ile hepatit B virüsü ve flavivirüsün engellenmesi ve tedavisi.
US6416763B1 (en) 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
EP1108036B1 (de) 1998-09-02 2010-06-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff
US6685948B1 (en) 1998-09-02 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Replication-defective dengue viruses that are replication-defective in mosquitoes for use as vaccines
ES2237420T5 (es) 1999-04-15 2010-03-03 Crucell Holland B.V. Produccion de proteina recombinante en una celula humana.
US6432411B1 (en) 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
EP1103610A1 (de) 1999-11-26 2001-05-30 Introgene B.V. Impfstoffherstellung von immortalisierten Säugetierzellinien
AU1813901A (en) 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
US7094411B2 (en) 2000-02-16 2006-08-22 The United States Of America As Represented By The Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
JP2003523978A (ja) 2000-02-18 2003-08-12 シャイアー・バイオケム・インコーポレイテッド ヌクレオシドアナログを用いるｆｌａｖｉｖｉｒｕｓ感染の処置もしくは予防するための方法
CN101525384A (zh) 2000-06-29 2009-09-09 艾博特公司 双特异性抗体及其制备方法和用途
WO2002015664A2 (en) 2000-08-23 2002-02-28 The New York Hospital Medical Center Of Queens Methods of preventing or treating west nile virus and other infections
US20030148261A1 (en) 2001-03-12 2003-08-07 Erol Fikrig Compositions and methods comprising West Nile virus polypeptides
WO2002103012A1 (en) 2001-06-15 2002-12-27 Crucell Holland B.V. Chimaeric phages
EP2283858A3 (de) 2001-07-27 2011-03-23 Wyeth LLC West-Nil-Vakzine
US20040258699A1 (en) 2002-02-11 2004-12-23 Bowdish Katherine S. Immunotherapeutics for biodefense
EP1572903A2 (de) 2002-02-11 2005-09-14 Alexion Pharmaceuticals, Inc. Immuntherapeutika zur bioabwehr
JP2005532057A (ja) 2002-07-09 2005-10-27 バクスター・インターナショナル・インコーポレイテッド 細胞を培養するための動物性タンパク質非含有培地
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
EP1601947A2 (de) 2002-10-31 2005-12-07 Health Research, Incorporated Diagnostischer test für west-nil-virus
NZ538808A (en) 2002-11-08 2008-03-28 Crucell Holland Bv Vaccines against west nile virus
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
JPWO2005007800A1 (ja) 2003-07-18 2007-04-12 持田製薬株式会社 抗血小板膜糖蛋白質ｖｉモノクローナル抗体
SG128680A1 (en) 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
ATE536376T1 (de) 2003-12-23 2011-12-15 Crucell Holland Bv Humanes bindungsmolekül gegen cd1a
US7074555B2 (en) 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
AU2004319642A1 (en) 2004-05-17 2005-11-24 Crucell Holland B.V. Methods for diagnosis of acute myeloid leukemia
NZ580607A (en) 2004-05-27 2011-05-27 Crucell Holland Bv Binding molecules capable of neutralizing rabies virus and uses thereof
WO2005123774A2 (en) 2004-06-15 2005-12-29 Erol Fikrig Antibodies to west nile virus polypeptides
CA2571404A1 (en) 2004-06-21 2005-12-29 Washington University Antibodies against west nile virus and therapeutic and prophylactic uses thereof
US7572456B2 (en) 2004-09-13 2009-08-11 Macrogenics, Inc. Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
CA2579523C (en) 2004-10-12 2016-04-12 Crucell Holland B.V. Atad3a-binding molecules for treatment, detection and prevention of cancer
WO2007011392A2 (en) 2004-10-14 2007-01-25 Washington University Crystal structure of domain 111 of west nile virus envelope protein-fab fragment of neutralizing antibody complex
NZ553701A (en) 2004-11-11 2009-12-24 Crucell Holland Bv Composition comprising SC03-014 and SC03-022 antibodies against SARS-CoV
WO2006056006A1 (en) 2004-11-23 2006-06-01 The University Of Queensland Equine west nile virus immunotherapy
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US8052974B2 (en) 2005-05-12 2011-11-08 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1893645A1 (de) 2005-06-23 2008-03-05 Crucell Holland B.V. Optimierung von antikörpern gegen das west-nile-virus
AU2006290736B2 (en) 2005-09-15 2011-09-15 Crucell Holland B.V. Method for preparing immunoglobulin libraries
EA018030B1 (ru) 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
WO2007141278A2 (en) 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof

Also Published As

Publication number Publication date
WO2006120230A3 (en) 2007-06-21
US8911738B2 (en) 2014-12-16
EP1879921B1 (de) 2011-04-27
US8052974B2 (en) 2011-11-08
AU2006245734A1 (en) 2006-11-16
AU2006245734C1 (en) 2012-05-24
CA2608058A1 (en) 2006-11-16
EP1879921A2 (de) 2008-01-23
CA2608058C (en) 2013-09-10
WO2006120230A2 (en) 2006-11-16
IL187321A (en) 2013-06-27
US20120076794A1 (en) 2012-03-29
IL187321A0 (en) 2008-04-13
US20100303801A1 (en) 2010-12-02
AU2006245734B2 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
IL187321A0 (en) Host cell specific binding molecules capable of neutralizing viruses and uses thereof
DK1749029T3 (da) Bindemolekyler, der kan neutralisere rabiesvirus, og anvendelser deraf
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
PH12014501776A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
BRPI0510475A (pt) adenovìrus quimérico para o uso no tratamento de cáncer
BR112013010857A2 (pt) imonoglubulinas de duplo domínio variável e usos das mesmas
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
ATE460473T1 (de) Immortalisierte entezelllinien zur viruserzeugung
WO2006067122A3 (en) Binding molecules capable of neutralizing west nile virus and uses thereof
ATE536376T1 (de) Humanes bindungsmolekül gegen cd1a
WO2007053189A3 (en) Compositions and methods for altering immune function
EA201201650A1 (ru) Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
EP2780460A4 (de) Modifizierte dna-bindende proteine und verwendungen davon
EA200801515A1 (ru) Лиганды, которые связывают il-4 и/или il-13
MX372950B (es) Anticuerpos.
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
DE602006012786D1 (de) System und Methode zur Konzentrierung und Lyse von Zellen oder Viren
BRPI0919236A8 (pt) Terapêutica e vacinas de combinação de gas
DE602007008360D1 (de) Aviäre telomerase reverse transkriptase
WO2008108830A3 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
CN110177810A (zh) 抗pcsk9抗体及其用途
EP2593548A4 (de) Zusammensetzung aus dem menschlichen papillomavirus-antigen e7 und verwendungen davon
EA201200182A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
UA110918C2 (uk) Інгібітори протеїнфосфатази-1 та їх застосування
EP1937717A4 (de) Penumbra-nukleinsäuremoleküle, proteine und anwendungen davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties